A new chimeric antigen receptor (CAR) T cell product consists of autologous T cells expressing an affinity-tuned glypican 3-targeted CAR and armoured to secrete a dominant-negative TGFβ receptor II. This cell product was tested in 36 patients with hepatocellular carcinoma and, although the initial efficacy results were promising, antigen loss and limited progression-free survival remain concerns. Here we discuss what else is needed to bring CAR T cells for solid tumours into the clinic.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Labanieh, L. & Mackall, C. L. CAR immune cells: design principles, resistance and the next generation. Nature 614, 635–648
https://doi.org/10.1038/s41586-023-05707-3(2023).Zhang, Q. et al. GPC3-specific dnTGFbetaRII-a...